Wall Street Analysts Predict a 76.37% Upside in AxoGen ( AXGN ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Axogen ( AXGN ) Q2 Revenue Jumps 18%
Axogen ( NASDAQ:AXGN ) , a regenerative medicine company focused on surgical solutions for peripheral nerve injuries, reported results on August 5, 2025. The standout news in this earnings release was a clear beat on both GAAP revenue and non-GAAP earnings, with GAAP revenue coming in at $56.7 ...
AxoGen ( AXGN ) Beats Q2 Earnings and Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of +100.00% and +7.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Waters ( WAT ) Surpasses Q2 Earnings and Revenue Estimates
Waters (WAT) delivered earnings and revenue surprises of +0.68% and +3.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Will PROCEPT BioRobotics Corporation ( PRCT ) Report Negative Earnings Next Week? What You Should Know
PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. ( NASDAQ: AXGN ) , a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor ...
AxoGen ( AXGN ) Earnings Expected to Grow: Should You Buy?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen ( AXGN ) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
AxoGen ( AXGN ) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -100% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc. Reports 2025 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. ( NASDAQ: AXGN ) , a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March ...
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
Axogen, Inc. to report 2025 first quarter financial results on May ...
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Axogen ( NASDAQ:AXGN ) , Butterfly Network ( NYSE:BFLY )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Lake Street analyst Frank Takkinen initiated coverage on Axogen, Inc.
Axogen, Inc. To Host Analyst & Investor Day on March 4th - Axogen ( NASDAQ:AXGN )
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. AXGN, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern.
Axogen, Inc. To Host Analyst & Investor Day on March 4th
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. ( NASDAQ: AXGN ) , a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern.
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results - Axogen ( NASDAQ:AXGN )
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. AXGN, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended ...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 - Axogen ( NASDAQ:AXGN )
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. AXGN, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, ...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Axogen, Inc. ( NASDAQ: AXGN ) , a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on ...
CRL Gears Up for Q4 Earnings: Here's What You Need to Know
Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.
STE Gears Up for Q3 Earnings: Here's What You Need to Know
STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.
ALGN Gears Up for Q4 Earnings: What Lies Ahead for the Stock?
Align Technology's fourth-quarter results are likely to reflect the strength in its Systems & Services business.
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock?
IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.
AxoGen, Inc. ( AXGN ) Soars to 52-Week High, Time to Cash Out?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen ( AXGN ) Moves 18.2% Higher: Will This Strength Last?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team ...
AxoGen, Inc. ( AXGN ) Hits Fresh High: Is There Still Room to Run?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA
Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - Applied Therapeutics ( NASDAQ:APLT ) , Reviva Pharmaceuticals ( NASDAQ:RVPH )
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer NEW YORK, Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Applied Therapeutics, Inc. APLT, a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the ...
Is AxoGen ( AXGN ) Stock Outpacing Its Medical Peers This Year?
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
DaVita Stock Gains 40.1% Year to Date: What's Behind the Rally?
Strength in kidney care services and expansion into international markets raise optimism for DVA stock.
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
Dexcom announces the first Generative AI platform in glucose biosensing.
Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
NVRO's continued technological innovations and business diversification plans raise optimism about the stock.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Add Accuray Stock in Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
HealthEquity Stock Falls Despite Q3 Earnings and Revenue Beat
HQY's fiscal third-quarter results benefit from robust HSA growth and improved gross margin. It also raises fiscal 2025 guidance.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
XRAY continues to gain traction from a robust product portfolio. However, the suspension of Byte's business and macroeconomic factors, such as weakened global demand, persist.
Strength Across Segments to Help CAH Stock Offset OptumRx Headwind?
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
Are Medical Stocks Lagging Doximity ( DOCS ) This Year?
Here is how Doximity (DOCS) and AxoGen (AXGN) have performed compared to their sector so far this year.
All You Need to Know About AxoGen ( AXGN ) Rating Upgrade to Buy
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in AxoGen ( AXGN ) ? Wall Street Analysts Think 31.18%
The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
